Global Health Ltd schedules analyst meets for August 26-27
- Global Health Limited to host physical analyst meets on August 26 and 27, 2026
- Meetings are one-on-one sessions with Motilal Oswal Financial Services Limited
- Disclosure made under SEBI LODR Regulation 30 on August 22, 2026
- Company confirms no unpublished price-sensitive information will be shared

*this image is generated using AI for illustrative purposes only.
Global Health Limited will host one-on-one physical meetings with Motilal Oswal Financial Services Limited on August 26 and 27, 2026. The engagements are part of the company's routine investor relations schedule.
Global Health disclosed the schedule in a filing dated August 22, 2026, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price-sensitive information will be shared during these sessions.
Meeting Schedule
The management team will engage with analysts from Motilal Oswal Financial Services Limited over two consecutive days. Both meetings are scheduled as physical, one-to-one interactions.
| Analyst Firm | Date | Type | Mode |
|---|---|---|---|
| Motilal Oswal Financial Services Limited | August 26, 2026 | One-to-one | Physical |
| Motilal Oswal Financial Services Limited | August 27, 2026 | One-to-one | Physical |
Rahul Ranjan, Company Secretary and Compliance Officer, signed the disclosure. The schedule remains subject to change due to unforeseen circumstances involving the analysts, investors, or the company.
Historical Stock Returns for Global Health
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.11% | -0.05% | +5.88% | +24.75% | +2.30% | +239.44% |
What specific strategic initiatives or financial metrics is Global Health likely to highlight to Motilal Oswal analysts during these one-on-one sessions?
How might the insights shared in these meetings influence Motilal Oswal's upcoming equity research report or rating for Global Health?
Are there any pending regulatory approvals or product launches that could be discussed as part of the company's routine investor relations update?

































